Biofrontera Inc. (NASDAQ:BFRI) Shares Shorted: Short Interest Up 82.1% in September

Biofrontera Inc. (NASDAQ:BFRI) was the target of a significant growth in short interest during the month of September. As of September 15th, there was short interest totaling 464,825 shares, a growth of 82.1% from the August 31st total of 255,272 shares. Currently, 3.4% of the shares of the company are sold short. Based on an average trading volume of 1,042,222 shares, the short-interest ratio is currently 0.4 days.

Biofrontera Price Performance

Shares of BFRI traded down $0.02 during midday trading on Tuesday, reaching $1.11. The stock had a trading volume of 77,654 shares, compared to its average volume of 419,480. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.18 and a quick ratio of 1.08. The company has a market capitalization of $16.44 million, a P/E ratio of -2.47 and a beta of 0.83. The firm’s 50 day moving average price is $1.32 and its 200-day moving average price is $1.10. Biofrontera has a 52 week low of $0.55 and a 52 week high of $1.66.

Biofrontera (NASDAQ:BFRI) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.05. Biofrontera had a negative net margin of 13.78% and a negative return on equity of 145.81%. The firm had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $9.50 million. On average, analysts forecast that Biofrontera will post -0.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on BFRI. Zacks Research upgraded shares of Biofrontera from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. Weiss Ratings upgraded shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Finally, Wall Street Zen cut Biofrontera from a “buy” rating to a “hold” rating in a report on Sunday, September 20th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Biofrontera presently has an average rating of “Hold”.

About Biofrontera

Biofrontera Inc (NASDAQ:BFRI) is a commercial-stage biopharmaceutical company focused on dermatology. The company develops and markets prescription therapies for the treatment of skin conditions, with an emphasis on products that address actinic keratosis and other dermatologic diseases.

Its principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, which is used in combination with the BF-RhodoLED lamp in photodynamic therapy for actinic keratoses. Biofrontera also provides the BF-RhodoLED photodynamic therapy lamp system used by healthcare professionals to activate the treatment.

Biofrontera Inc is based in the United States and operates as part of the broader Biofrontera corporate group, which has German roots and an international dermatology business.